Archer Investment Corp Acquires Shares of 73,546 Pfizer Inc. $PFE

Archer Investment Corp bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 73,546 shares of the biopharmaceutical company's stock, valued at approximately $1,771,000.

Other institutional investors have also recently made changes to their positions in the company. Handelsbanken Fonder AB lifted its stake in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock valued at $59,295,000 after buying an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock valued at $132,365,000 after purchasing an additional 745,213 shares during the period. Leuthold Group LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $4,887,000. North Dakota State Investment Board acquired a new position in shares of Pfizer during the fourth quarter worth approximately $5,348,000. Finally, Park National Corp OH boosted its position in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock worth $5,829,000 after buying an additional 186,053 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.2%

NYSE:PFE opened at $27.95 on Friday. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company has a market cap of $159.31 billion, a PE ratio of 36.78 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a 50-day moving average of $25.55 and a 200-day moving average of $26.30.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer's dividend payout ratio is currently 226.32%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PFE. UBS Group reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Wolfe Research reissued an "underperform" rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. JPMorgan Chase & Co. reduced their price objective on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. BMO Capital Markets decreased their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. Finally, Weiss Ratings cut shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source